2011 ASH Program Book - American Society of Hypertension

More documents

Recommendations

Info

8More than References: 1. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816. 2. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. 3. Black HR, Elliott WJ, Grandits G, et al; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289(16):2073-2082. 4. Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936 ©2011 Novartis
Visit booth #1100 to find out more out of 10 patients may need more than 1 agent to get to BP goal 1-4 Printed in USA 4/11 DIO-1052602
Page 1: American Society of Hypertension, I
Page 6 and 7: Past Presidents of the American Soc
Page 8 and 9: Program Color Key The pages of this
Page 10 and 11: Letter continued Following the Awar
Page 12 and 13: General Information continued Discl
Page 14 and 15: General Information continued ASH S
Page 16 and 17: General Information continued ASH P
Page 18 and 19: 2011 ASH Corporate Members Boehring
Page 20 and 21: ASH Leadership 2010-2011 Board of D
Page 22 and 23: Special Lecture Monday, May 23, 201
Page 24 and 25: Young Scholar Award* Monday, May 23
Page 26 and 27: Special Lecture Monday, May 23, 201
Page 28 and 29: 2011 Abstract Reviewers Lawrence J.
Page 30 and 31: More than half of hypertensive pati
Page 32 and 33: Poster Category Presentation Poster
Page 34 and 35: 2011 ASH Faculty Rajiv Agarwal, MD
Page 36 and 37: 2011 ASH Faculty continued David L.
Page 38 and 39: American Society of Hypertension, I
Page 40 and 41: Program Color Key The pages of this
Page 42 and 43: MAY 21 Saturday Morning Hypertensio
Page 44 and 45: MAY 21 Sessions Saturday Afternoon
Page 50 and 51: MAY 21 Posters Saturday Evening Pos
Page 52 and 53:
MAY 22 Sunday morning Sessions cont
Page 54 and 55:
MAY 22 Sessions Sunday Morning 9:00
Page 56 and 57:
MAY 22 Sessions Sunday Morning 9:00
Page 58 and 59:
MAY 22 Debates Sunday Morning 11:00
Page 60 and 61:
MAY 22 Plenary Session I Sunday Aft
Page 62 and 63:
MAY 22 Special Sessions Sunday Afte
Page 64 and 65:
MAY 22 Sessions Sunday Afternoon 3:
Page 66 and 67:
MAY 23 Satellite Symposium 6:00 AM
Page 68 and 69:
MAY 23 Sessions Monday morning 8:00
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
MAY 23 Plenary Session II Monday Af
Page 80 and 81:
MAY 24 Sessions Tuesday Morning 8:1
Page 82 and 83:
MAY 24 Sessions Tuesday Morning 10:
Page 84 and 85:
MAY 24 Sessions Tuesday Morning 10:
Page 87 and 88:
2011 American Society of Hypertensi
Page 89 and 90:
Saturday Afternoon MAY 21 Posters 4
Page 91 and 92:
Saturday Afternoon MAY 21 Posters P
Page 93 and 94:
Saturday Afternoon MAY 21 Posters E
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Saturday Afternoon MAY 21 Posters I
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Sunday Morning MAY 22 Posters 10:00
Page 109 and 110:
Sunday Morning MAY 22 Posters 10:00
Page 111 and 112:
Sunday Morning MAY 22 Posters PO-13
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Monday Morning Afternoon MAY 21 23
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Faculty Disclosure Listing Rajiv Ag
Page 149 and 150:
Faculty Disclosure Listing continue
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
ASH Hypertension Resource Pavilion
Page 159 and 160:
2011 ASH Innovations Theater Rhinel
Page 161 and 162:
2011 ASH Exhibitors continued A & D
Page 163 and 164:
2011 ASH Exhibitors continued David
Page 165 and 166:
2011 ASH Exhibitors continued Inter
Page 167 and 168:
2011 ASH Exhibitors continued Novar
Page 169 and 170:
2011 ASH Exhibitors continued Wiley
Page 171 and 172:
Author Index Berezina, Aelita V., 8
Page 173 and 174:
Author Index Eguchi, Kazuo, 110, 13
Page 175 and 176:
Author Index Ikeda, Yasuhiro, 116 I
Page 177 and 178:
Author Index Makani, Harikrishna, 1
Page 179 and 180:
Author Index Rabelink, Ton J., 93 R
Page 181 and 182:
Author Index Tatsis, I., 92, 124 Ta
Page 183 and 184:
Hilton New York Floor Plans Second
Page 185 and 186:
Hilton New York Floor Plans Fourth
Page 187 and 188:
Tekamlo (aliskiren and amlodipine)
Page 189 and 190:
25% (systolic) and 27% (diastolic)
Page 191 and 192:
Two cases of angioedema with respir
Page 193 and 194:
amlodipine and sildenafil were used
Page 195 and 196:
Amlodipine besylate Single oral dos
show all

2011 ASH Program Book - American Society of Hypertension

Create successful ePaper yourself

Delete template?

Save as template?